Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and nine months ended September 30, 2024
Business Overview: Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead product candidate, PALI-2108, is a prodrug inhibitor targeting phosphodiesterase-4 (PDE4) for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company operates under a license agreement with Giiant Pharma, Inc. for PALI-2108.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| License Revenue | $0 | $0 | $0 | $250 |
| Total Operating Expenses | $3,593 | $3,778 | $11,477 | $10,166 |
| - Research & Development | $2,137 | $2,104 | $6,979 | $5,522 |
| - General & Administrative | $1,456 | $1,674 | $4,498 | $4,644 |
| Net Loss | $(3,487) | $(3,596) | $(11,094) | $(9,329) |
| Cash and Cash Equivalents (End of Period) | $8,040 | $12,432 | $8,040 | $15,312 |
| Accumulated Deficit | $(132,600) | $(118,535) | $(132,600) | $(118,535) |
| Net Cash Used in Operating Activities (9M) | $(9,812) | $(8,387) | $(9,812) | $(8,387) |
| Net Cash Provided by Financing Activities (9M) | $5,420 | $11,320 | $5,420 | $11,320 |
Material Changes vs. Prior Period
- Revenue: No license revenue was recognized in the nine months ended September 30, 2024, compared to $250,000 in the same period in 2023. The prior year revenue was derived from a milestone achievement under the Newsoara Co-Development Agreement.
- Operating Expenses: Total operating expenses increased by 13% ($1.3 million) for the nine months ended September 30, 2024, compared to the prior year. This increase was driven primarily by a $1.5 million rise in Research and Development (R&D) expenses, largely due to $4.3 million in joint development costs for PALI-2108 and increased drug manufacturing costs. General and Administrative (G&A) expenses decreased by 3% due to lower professional fees, insurance costs, and board fees.
- Net Loss: Net loss increased by 19% to $11.1 million for the nine months ended September 30, 2024, compared to $9.3 million in the prior year period.
- Liquidity: Cash and cash equivalents decreased by approximately $4.4 million during the nine months ended September 30, 2024, primarily due to operating cash outflows, partially offset by financing activities.
Guidance, Outlook, and Risks
- Clinical Progress: On October 9, 2024, Health Canada issued a No Objection Letter (NOL) for a Phase 1 clinical study of PALI-2108 for ulcerative colitis. The company commenced enrollment and dosed its first subjects on November 6, 2024. Topline data is anticipated in Q2 2025. An Investigational New Drug (IND) application for the U.S. is anticipated in 2025.
- Capital Resources: As of September 30, 2024, the company held $8.0 million in cash. Management believes this is sufficient to fund operations through the first quarter of 2025. However, the company has expressed substantial doubt about its ability to continue as a going concern for a period of one year following the issuance of the financial statements due to recurring losses and negative cash flows.
- Recent Financings: In May 2024, the company completed a private placement raising net proceeds of approximately $3.5 million. In February 2024, a warrant inducement transaction raised net proceeds of approximately $2.2 million.
- Material Weakness: The company identified a material weakness in internal control over financial reporting related to a lack of segregation of duties and formalized processes for journal entries and account reconciliations. Remediation efforts are ongoing but the weakness remains as of September 30, 2024.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital to fund operations beyond Q1 2025, dependence on the Giiant license agreement, and potential delisting from Nasdaq if the stock price falls below $1.00 for 30 consecutive business days.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.0 million cash balance to fund the Phase 1 trial and operations through Q1 2025, and assess the timeline and terms for potential future capital raises.
- Going Concern Status: Review the specific conditions and events cited by management that raise substantial doubt about the company's ability to continue as a going concern.
- Clinical Trial Milestones: Monitor the progress of the Phase 1 trial in Canada, specifically patient enrollment rates and safety data, as these are critical for future funding and regulatory approval.
- Internal Controls: Track the progress of remediation efforts regarding the material weakness in internal controls over financial reporting.
- License Agreement Terms: Review the amended Giiant License Agreement to understand the revised milestone payments and payment cap, and the company's obligations regarding joint development costs.